NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/10/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization43.82 mln
Float30.64 mln
Earnings Date11/18/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
-4.3
Highly reliable
Relative Strength
28
/ 100
Underperforming
Debt / Equity
0.34
Low leverage
Pre-Tax Margin
-691%
Severely loss-making
ROE
-59.66
Deeply negative
Business Description
Metagenomi Therapeutics Inc. is a California-based company focused on developing gene-editing treatments that aim to permanently correct the underlying causes of serious diseases. Its lead program targets hemophilia, seeking to protect patients from dangerous bleeding episodes and long-term joint damage. The company also works with Ionis Pharmaceuticals on several programs addressing conditions such as high triglycerides, a rare protein-buildup disorder, and difficult-to-treat high blood pressure. Founded in 2016 and based in Emeryville, California, the company operates exclusively in the United States.
